Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Q-FREE – MINUTES EXTRAORDINARY GENERAL MEETING 9 FEBRUARY 2016

Oslo 10 February 2016:An Extraordinary General Meeting in Q-Free ASA was held on 9 February 2016 at Hotel Continental in Oslo, Norway.All proposals on the agenda were adopted cf. the notice that was published on the Oslo Stock Exchange on 21 January 2016. The proposed elections to the Board of Directors and Nomination committee were approved in accordance with the recommendation from the Nomination committee. The Board of Directors will after this be comprised of the following members: - Charlotte Brogren Karlberg (Chairman of the Board)- Ragnhild Wahl- Tore Valderhaug-

YEAR-END REPORT JANUARY – DECEMBER 2015

(For complete interim report see attached file)  · Profit after net financial items for the whole of 2015 was SEK 259 (114) million, our best annual result in the current structure. · Profit after net financial items for the fourth quarter of 2015 was SEK 1 (13) million, a weak result mainly relating to problems in connection with the production start-up after the maintenance shutdown in Vallvik Mill. · Cash flow before investments for the whole of 2015 was strong and totalled SEK 335 (104) million. Rottneros is debt-free and at year-end cash and cash equivalents totalled SEK 169 (

Merger plan and documents

Reference is made to stock exchange announcement 8 February 2016 regarding the proposed merger of Bonheur ASA and Ganger Rolf ASA (the "Companies"). The merger plan resolved by the boards of the Companies constituted by the competent directors has now been published and is enclosed to this announcement in accordance with section 10.3 (2) of the Oslo Stock Exchange's continuing obligations for stock exchange listed companies. The Companies' annual reports for 2012, 2013 and 2014 together with the financial report for the first half year of 2015 have previously been published through the Oslo

Principal owner of Diamyd Medical transfers subscription rights to endowment insurance

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announed today that its principal owner, and also the CEO of the Company, Anders Essen-Möller, who will subscribe for his full share of the Company’s ongoing share issue corresponding to approximately 21 percent or MSEK 4.6 of the total share issue of MSEK 22.1, has transferred 3,613,455 of his Series B subscription rights in Diamyd Medical to an endowment insurance. Accordingly, the corresponding new Series B shares, 1,204,485, will be held in an endowment insurance. “There are certain tax advantages to holding securities in

Changes to Ovako’s board

· Joakim Olsson has been elected as new Chairman of Ovako board · Johan Pernvi has been elected as new board member of Ovako · Finn Johnsson and Björn Nilsson will leave the boardJoakim Olsson has been elected new chairman of Ovako board, where he has been a member since last year. Joakim Olsson replaces Finn Johnsson. Joakim Olsson is Senior Industry Expert at Triton Partners. He has extensive experience of leading and developing major international organisations in industry, energy and automation. He was previously president and CEO at SAG Group GmbH and Haldex AB (publ), and has

Merger plan and documents

Reference is made to stock exchange announcement 8 February 2016 regarding the proposed merger of Bonheur ASA and Ganger Rolf ASA (the "Companies"). The merger plan resolved by the boards of the Companies constituted by the competent directors has now been published and is enclosed to this announcement in accordance with section 10.3 (2) of the Oslo Stock Exchange's continuing obligations for stock exchange listed companies. The Companies' annual reports for 2012, 2013 and 2014 together with the financial report for the first half year of 2015 have previously been published through the Oslo

YEAR-END REPORT 2015

THE FULL YEAR AND THE FOURTH QUARTER · Net sales increased to MSEK 69.1 (30.1), whereof the fourth quarter MSEK 57.4 (8.1) · Net loss was MSEK -78.2 (-59.3), whereof the fourth quarter MSEK -24.7 (-21.8) · Loss per share was SEK-1.57 (-1.60), whereof the fourth quarter SEK -0.49 (-0.59) · Cash flow from operating activities was MSEK 73.8 (-46.3), whereof the fourth quarter MSEK 120.5 (-10.7) · Cash and cash equivalents at the end of the period totalled MSEK 76.4 (51.6) · Acquisition of the companies Tanomed AB, Apropharm AS/DNE Sverige AB, Swereco Group and MedCore AB

Pricer AB – Year-end report 2015

Strong result and cash flow concludes 2015, the Board proposes to resume dividend Fourth quarter 2015 · Net sales of SEK  178.5 (173.2) M, an increase of 3 percent compared to last year · Operating profit of SEK 7.4 (7.2[2]) M and profit for the period of SEK 7.9 (-5.1) M · Cash flow from operating activities increased to SEK 92.7 (56.8) M · Order intake of SEK 108 (115) M, a decrease of 6 percent compared to last year · The backlog* is approximately SEK 63 M, whereof the majority is expected to be invoiced in the first quarter of 2016 · Framework agreement signed

KARO BIO CARRIES OUT A FULLY GUARANTEED RIGHTS ISSUE OF MSEK 250

THIS PRESS RELEASE MUST NOT BE PUBLISHED, ANNOUNCED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE U.S. OR ANY OTHER JURISDICTION WHERE PUBLICATION, ANNOUNCEMENT OR DISTRIBUTION OF THE INFORMATION DOES NOT COMPLY WITH APPLICABLE LAW.STOCKHOLM, February 12, 2016 – The Board of Karo Bio AB (publ) has resolved to carry out a rights issue with preferential rights for the existing shareholders. The terms of the rights issue entail that four (4) existing shares will entitle to subscription for one (1) new share at a subscription price of SEK 20.00. Subscription for new shares shall take place

NOTICE OF EXTRAORDINARY GENERAL MEETING IN KARO BIO AB (PUBL)

Shareholders in Karo Bio AB (publ) are hereby called to an extraordinary general meeting on Wednesday, March 16, 2016 at 3:00 p.m. at Karo Bio’s offices at Novum Research Park (level 8, elevator E), Hälsovägen 7 in Huddinge Right to attend Entitled to attend the extraordinary general meeting are those who are both registered shareholders in the share register held by Euroclear Sweden AB at the record date March 10, 2016 and have given notification to the company of their intention to attend the extraordinary meeting not later than March 10, 2016, at 4.00 p.m. Shareholders with

Biohit Oyj’s new B-shares have been registered with the Trade Register as a part of the share exchange agreement with Genetic Analysis AS

Biohit Oyj Stock Exchange Release February 12, 2016 at 09:30 local time (EET) As a part of the share exchange agreement announced on January 5, 2016 Biohit Oyj has executed a directed share issue of 350,000 pcs Biohit Oyj’s new class B shares to Genetic Analysis AS. The new class B shares have been registered with the Trade Register on February 12, 2016, and the shares carry with them the same shareholder rights as the outstanding class B shares as of the date of the registration. The trading in the new shares is expected to commence as of February 15, 2016 on NASDAQ OMX Helsinki

Year-End Report 1 January – 31 December 2015

Fourth quarter (1 October - 31 December 2015) · Net sales for the quarter were MSEK 151 (84). · The operating profit before depreciation (EBITDA) was MSEK 85 (88) before and MSEK 48 (86) after non-recurring items. Non-recurring items were MSEK -37, of which MSEK -32 refers to impairment in associates in the third quarter that was fully recognised in the consolidated financial statements only in the fourth quarter while MSEK -5 is attributable to costs in connection with a reorganisation. · Earnings before tax were MSEK 33 (29) before and MSEK -4 (26) after non-recurring items.

BioGaia AB – Year-end report 2015

Managing Director’s comments:“We cannot but feel happy and satisfied with the past year. Thanks to sales growth of 16% after exchange rate adjustments, we are now approaching sales of one half billion. According to our data, the total market for probiotic dietary supplements is expanding by around 8% annually, which means that we are winning market shares. Our operating profit reached SEK 152 million, resulting in an operating margin of over 31%. And this was achieved despite expenses of SEK 20.6 million for our subsidiary IBT. Without these expenses our operating margin would have been a

Type 2 diabetes drug can exhaust insulin-producing cells

[PRESS RELEASE, 12 FEB. 2016] Long-term use of liraglutide, a substance that helps to lower blood sugar levels in patients with type 2 diabetes, can have a deteriorating effect on insulin-producing beta cells, leading to an increase in blood sugar levels. This according to a study on mice implanted with human insulin-producing cells conducted by a team of scientists from Karolinska Institutet, Sweden, and the University of Miami, USA. The researchers flag the possible consequences of this popular form of therapy in the next issue of the journal Cell Metabolism.Blood-sugar suppressors in the

SAS Annual Report 2014/2015

At a Board meeting of SAS AB, the November 2014 – October 2015 annual report for SAS and its parent company SAS AB was presented and approved. The annual report is now available on the internet, www.sasgroup.net under Investor Relations, and will be printed and distributed to shareholders who have notified their interest to receive a copy via SAS website. The annual report includes an updated dividend policy. Dividends to holders of common shares can be paid from value-creation whereby SAS’s return on invested capital exceeds the average cost of capital. The dividend should take into

Year-end report ProfilGruppen January 1 – December 31, 2015

Significant improvement of the result for the year   Fourth quarter · Turnover MSEK 234.7  (208.6), 13 percent increase compared to previous year · Operating profit MSEK 4.9 (5.3), one-time costs affected the resultnegatively with MSEK 2.5 (positively 2.7) · Net income MSEK 2.4 (2.6) · Cash flow from ongoing operations MSEK 22.9 (11.7) · Earnings per share SEK 0.42 (0.35) Year 2015 · Turnover MSEK 980.2 (808.6), 21 percent compared to previous year · ProfilGruppen signed the historically largest business contract ever, for about 200 million SEK per year ·

Proposal for distribution and separate listing of BioGaia’s subsidiary Infant Bacterial Therapeutics

The board of directors of BioGaia AB (publ) (“BioGaia”) has resolved to propose to an Extraordinary General Meeting in BioGaia on 18 March 2016 to distribute the shares in the subsidiary Infant Bacterial Therapeutics AB (publ) (“IBT”) to the shareholders of BioGaia. In connection with the execution of the dividend, IBT will apply for a listing of its series B shares on Nasdaq First North. To finance IBT’s first clinical trial, the company has, as previously communicated, a capital need of approximately SEK 100 million, which is planned to be raised through a rights issue with preferential

CORRECTION: FINANCIAL STATEMENTS BULLETIN 2015: DESTIA’S REVENUE AND ORDER BOOK INCREASE, OPERATING PROFIT FALLS SLIGHTLY SHORT OF THE PREVIOUS YEAR

Destia Group Plc STOCK EXCHANGE RELEASE 12.2.2016 at 9.00 (CET +1) Destia corrects the financial statements bulletin 2015 sent out 11.2.2016 at 14:30 as follows: in the first paragraph of “Proposal by the Board on the use of distributable assets”, the Destia Group Plc’s FAS-compliant loss EUR 3,051,660.32was corrected as profit EUR 3,051,660.32. Corrected release and report can be found below. Destia’s financial statements bulletin 2015 FINANCIAL STATEMENTS BULLETIN 2015: DESTIA’S REVENUE AND ORDER BOOK INCREASE, OPERATING PROFIT FALLS SLIGHTLY SHORT OF THE PREVIOUS YEAR

ÅF builds new dairy for DalsSpira

ÅF has signed a contract with DalsSpira Mejeri for the delivery of a new dairy plant. The contract is worth about SEK 12 million with the new dairy being completed in June 2016. DalsSpira needs to increase its production of goat’s and cow’s milk products and ÅF has been contracted to deliver the dairy plant as an end-to-end solution in Dalsland, Sweden. The contract covers project planning and management along with installation of processing equipment including electricity and automation. ÅF is also responsible for relocating the current goat’s milk dairy to the new plant, which will

Orkla ASA: Mandatory notification of trade - options

On 11 February, in connection with Orkla's former management option programme, 50,000 options in Orkla-shares were exercised at a strike price of NOK 42.53 per share. After this transaction, the total number of options issued in Orkla shares under the management option programme is 2,647,000. Orkla owns 1,806,738 treasury shares. Orkla ASAOslo, 12 February 2016   Ref.: Investor RelationsElise HeidenreichTel.: +47 951 41 147     This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Year-End Report for Duni AB (publ) 1 January – 31 December 2015

Stable earnings and strong balance sheet1 October – 31 December 2015 · Net sales amounted to SEK 1,170 m (1,134). Adjusted for exchange rate changes, net sales increased by 1.0%. · Earnings per share, for continuing operations, after dilution amounted to SEK 2.32 (2.23). · The operating margin continues to strengthen, reaching 14.6% (14.5%) in the quarter. · Stable core business with expanding Meal Service. 1 January – 31 December 2015 · Net sales amounted to SEK 4,200 m (3,870). Adjusted for exchange rate changes, net sales increased by 4.4%. · Earnings per share,

Results for 2015

Strong cash flow despite tough marketThe quarter · Sales were SEK 12,499 (15,200) million · Operating profit before depreciation/amortization, excluding items affecting comparability, was SEK 157 (1,051) million · Operating profit/loss, excluding items affecting comparability, was SEK -802 (118) million · Operating loss after financial items, excluding items affecting comparability, was SEK -1,051 (-82) million · Earnings per share were SEK -1.23 (-2.39) · Items affecting comparability had an impact of SEK -65 (-1,322) million on the result after tax · Operating cash

Invitation to Exel Composites’ 2015 results briefing on 19 February 2016

Exel Composites Plc            Stock exchange release        12.2.2016        8.30 a.m. EET  Invitation to Exel Composites’ 2015 results briefing on 19 February 2016 Exel Composites Plc will publish its financial statements bulletin on Friday 19 February 2016 at 9.00 a.m. EET. The financial statements bulletin will be available on the Company’s website at www.exelcomposites.com > Investor. A financial results briefing will be held the same day at 12.30 p.m. EET at Scandic Hotel Simonkenttä in the Tapiola cabinet at the address of Simonkatu 9, Helsinki, Finland. The briefing will be

There are no items matching the current filter
There are no more items matching the current filter
Back to top